Each year, 70 million Americans are affected by gastrointestinal diseases, including colorectal cancer, which in aggregate result in 250,000 deaths annually and $140 billion in medical costs 1. To effectively manage GI health, one must directly evaluate the cells lining the GI tract — enterocytes. There are two methods to isolate these enterocytes: 1) an endoscopic procedure (i.e., colonoscopy, upper endoscopy, or sigmoidoscopy) to obtain a biopsy, or 2) isolation of the enterocytes from stool samples.
Endoscopic procedures are inconvenient, invasive and expensive, so many patients avoid them. For example, in colorectal cancer, up to 40% of patients fail to get screened, primarily due to the inconvenience and invasiveness of a colonoscopy 2. As a result, colorectal cancer remains the third most common type of cancer in the US and inflicts an unacceptably high mortality rate.
Fortunately, evaluating biomarkers from enterocytes in stool samples presents the possibility for a patient-friendly and effective means of assessing GI health. Geneoscopy’s platform provides access to these biomarkers, enabling the development of non-invasive diagnostic tests to address major unmet clinical needs.
There are many different potential applications for Geneoscopy’s technology — screening, diagnosis, therapeutic selection, monitoring, surveillance, drug development — that span a number of different disease indications, including colorectal cancer, inflammatory bowel disease, infectious disease, necrotizing enterocolitis, celiac disease, irritable bowel syndrome, and diabetes. Leveraging its unique RNA extraction methodology, Geneoscopy’s goal is to improve the prevention, detection, and treatment of GI disease across this entire continuum.